This webinar is a recorded presentation of a live broadcast and includes a pre-test, the presentation, handout, the audience QA, and a post-test. Continuing education credit is available for the webinar.
Description: This presentation will continue the discussion of the potential use of PARP inhibitors with an emphasis on advances in laboratory practices for identification of homologous recombination deficiency in sequencing data. This session will examine the challenges inherent to biomarker testing for PARPi response, including for patients whose tumors lack mutations in BRCA1/2.
Duration: 1 hr
Level of Instruction: Basic
Last day to purchase course and claim credit: October 29, 2021
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Association for Molecular Pathology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CMLE Credit: The ASCP designates this activity for a maximum of 1.0 Continuing Medical Laboratory Education (CMLE) credit hour. CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.
SAM Credit: This activity is approved by the American Board of Pathology for up to 1.0 SAM credit. Physicians should claim only credit commensurate with the extent of their participation in the activity. Learners must pass the post-test with a score of 80% or higher and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for an accrediting board other than the ABP, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
“Targeting DNA Repair Pathways: Current and Future Implications of PARP Inhibitors” is an up-to-date and useful three-part webcast series that will cover: 1. The mechanism of action of PARP inhibitors and the science of Homologous Recombination Deficiency (HRD) testing, 2. Laboratory considerations (from sample acquisition to result reporting) for HRD testing, and 3. Clinical considerations for testing and treatment and the need for genetic counseling.
This program has been supported through educational grants from AstraZeneca & Merck
You may also be interested in:
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
October 29, 2019
American Board of Pathology
Self-Assessment Module: 1.00
American Medical Association
Continuing Medical Education: 1.00
American Society for Clinical Pathology
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00